Afatinib
Brand: Giotrif (global) / Afatinib (IN/BD)
Anticancer
EGFR/HER2 irreversible TKI
Pharmacokinetics
| Half-life | 37 hours |
| Tmax | 2 h |
| Bioavailability | 92 % (approx) |
| Protein Binding | 95 % |
| Volume of Distribution | 3 L/kg (approx) |
| Clearance Route | renal |
| Active Metabolites | no |
| Notes | Higher GI toxicity. Use loperamide early. Better in exon 19 deletions. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Rash, diarrhoea, stomatitis
Contraindications:
Severe renal impairment
Precautions:
Aggressive loperamide for diarrhoea